Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Saudi Pharm J ; 31(9): 101732, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37638220

ABSTRACT

Epilepsy is a chronic neurological disorder marked by recurrent seizures, significantly affecting the population in Saudi Arabia across all age demographics. The global prevalence of active epilepsy is around 6.38/1,000 persons and in the Arabian region, the median prevalence of active epilepsy is 4.4/1,000 persons. However, over 75% of individuals are untreated. Consequently, the development of therapeutic strategies with increased efficacy and safety profiles is essential to improve the survival rate among epilepsy patients. The current study integrates network pharmacology along with Bioinformatics approaches to explore the potential molecular mechanisms of local flora of Saudi Arabia including Solanum incanum, Abrus precatorius, Withania somnifera, and Azadirachta indica in epilepsy treatment. In the preliminary phase, data related to the bioactive components of the local plants and the associated target genes of both these plants and epilepsy were gathered from scientific literature and open-source databases. This data was then analyzed to identify common targets between the plants and ovarian cancer. Based on these common targets, a protein-protein interaction (PPI) network was constructed utilizing the STRING database, which was subsequently incorporated into the Cytoscape software for identification of hub genes based on their degree of connectivity. Lastly, an interplay network depicting the associations between the compounds and the overlapping genes was formulated via Cytoscape, to study the potential network pharmacology implications of these active compounds in relation to ovarian cancer. Following that, a compound-target protein-pathway network was constructed which uncovered that namely abrectorin, genistin, (+)-catechin, precatorine, (+)-ascorbic acid, licoflavanone, skrofulein, stigmasterone, 5,7-Dihydroxy-4'-methoxy-8,3'-di-C-prenylflavanone could potentially be used as antagonists for the therapeutic management of epilepsy by targeting TNF and TP53 proteins. Furthermore, the implementation of molecular docking reinforces the binding affinity of the compound, indicating a robust stability of the forecasted compounds at the docked site. This research lays both a theoretical and experimental groundwork for more profound investigations and establishes a practical method for the strategic employment of active compounds in the development of anti-epileptic therapeutics.

2.
Molecules ; 28(4)2023 Feb 19.
Article in English | MEDLINE | ID: mdl-36838959

ABSTRACT

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common form of liver cancer that occurs in hepatocytes. Although many chemical drugs, e.g., cisplatin, methotrexate, taxis, and doxorubicin are used to treat HCC, there have been numerous reports related to the side effects of these drugs (e.g., emerging drug resistance, bone marrow failure, and gastrointestinal disorders). These issues led scientists to search for the novel anti-cancer drugs, mainly in natural products with greater efficiency and less toxicity. The current survey was intended to assess the anti-cancer effects of queen bee acid (10-Hydroxy-2-Decenoic Acid, 10-HDA) and its cellular mechanisms against the human hepatoma cell line HepG2. MATERIALS AND METHODS: The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was used to evaluate the effect of 10-HDA on the viability of HepG2 cells. The initial and late apoptosis in the HepG2 cells treated with 10-HDA were assessed by the Annexin-V (AV) assay. The level of the gene and protein expression of some apoptosis genes (e.g., caspase-3, Bcl-2-associated X protein (BAX), and B-cell lymphoma protein 2 (Bcl-2)), Poly (ADP-ribose) polymerases (PARP), and miRNA-34a (miR-34a), were measured by real-time PCR and Western blot. RESULTS: The obtained findings revealed that HepG2 cell viability was markedly reduced (p < 0.01) following exposure to 10-HDA in a dose-dependent matter. The calculated half maximal cytotoxic concentration (CC50) value of 10-HDA was 59.6 µg/mL for HepG2 cells, while this value for normal THLE-3 cells was 106.4 µg/mL. We found that 10-HDA markedly elevated (p < 0.01) the percentage of necrotic and apoptotic cells from 0.94 to 9.7 and 27.6%, respectively. The real-time PCR results showed that the expression levels of the caspase-3, Bax, and miR-34a genes were significantly (p < 0.001) elevated. Contrary to these results, a significant (p < 0.01) reduction in the expression level of the Bcl2 gene was observed. The levels of protein expression of Caspase-3, PARP, and Bax were markedly elevated following exposure of HepG2 cells to 10-HDA at » CC50, ½ CC50, and CC50. The level of protein expression of Bcl-2 was markedly reduced following exposure of HepG2 cells to 10-HDA at » CC50, ½ CC50, and CC50 (p < 0.01). CONCLUSION: The current results confirmed the potent in vitro cytotoxic effects of 10-HDA on HepG2 cells with no significant cytotoxic effects on normal cells. Although its mechanisms of action have not been fully studied, the induction of apoptosis via different pathways was determined as one of the principle mechanisms of action of 10-HDA against HepG2 cells. Nevertheless, additional surveys must be performed to clearly understand the mechanisms of action and safety of this fatty acid.


Subject(s)
Antineoplastic Agents , Carcinoma, Hepatocellular , Liver Neoplasms , MicroRNAs , Humans , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , bcl-2-Associated X Protein/genetics , Caspase 3/metabolism , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Apoptosis , Proto-Oncogene Proteins c-bcl-2/genetics , Antineoplastic Agents/pharmacology , Hep G2 Cells , MicroRNAs/therapeutic use
3.
Pak J Biol Sci ; 24(2): 188-192, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33683047

ABSTRACT

BACKGROUND AND OBJECTIVE: Male fertility depends on the availability of the potent androgen called testosterone. Testosterone production is regulated by the hypothalamic anterior pituitary axis. Two anterior pituitary hormones Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) are involved in spermatogenesis and testosterone production, respectively. Hypoxia, resulting from high altitude, may induce a change in these four hormones and may affect male fertility. This study was done to evaluate and compare the changes that occur in FSH, LH, testosterone and prolactin in males lived in moderate versus low altitude. MATERIALS AND METHODS: This study was conducted on 300 individuals who were categorized based on the altitude of their habitat into two equal groups, namely: Inhabitants at moderate altitudes and inhabitants at low altitudes. A venous blood sample was collected from each individual to measure the levels of FSH, LH and prolactin. RESULTS: Both LH and testosterone levels were significantly lower in high altitude inhabitants compared with low altitude inhabitants (p<0.01). The FSH level showed a significant statistical difference between two groups with a lower level in individuals living at high altitudes compared with low altitude inhabitants but on a value (p<0.05). CONCLUSION: Moderate altitude hypoxia suppresses LH, FSH and testosterone levels as much as high altitude hypoxia does and these changes may depend on prolactin level.


Subject(s)
Acclimatization , Altitude , Follicle Stimulating Hormone, Human/blood , Luteinizing Hormone/blood , Prolactin/blood , Testosterone/blood , Adult , Fertility , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...